Applied Genetic Technologies Co. (NASDAQ:AGTC) Given Consensus Rating of “Buy” by Brokerages – Defense World
Posted by admin on Jun 4th, 2022 
Shares of Applied Genetic Technologies Co. (NASDAQ:AGTC – Get Rating) have been assigned an average rating of “Buy” from the nine brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $11.50.
AGTC has been the subject of several recent analyst reports. StockNews.com initiated coverage on Applied Genetic Technologies in a report on Thursday, March 31st. They issued a “sell” rating for the company. Stifel Nicolaus reiterated a “buy” rating and set a $10.00 target price on shares of Applied Genetic Technologies in a report on Thursday, April 14th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Applied Genetic Technologies in a report on Tuesday, May 17th. Roth Capital reiterated a “buy” rating on shares of Applied Genetic Technologies in a report on Tuesday, February 8th. Finally, Chardan Capital reiterated a “buy” rating on shares of Applied Genetic Technologies in a report on Monday, April 11th.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cantor Fitzgerald L. P. purchased a new position in Applied Genetic Technologies in the 1st quarter worth approximately $2,524,000. Virtu Financial LLC acquired a new position in shares of Applied Genetic Technologies in the 1st quarter valued at approximately $75,000. Portolan Capital Management LLC raised its position in shares of Applied Genetic Technologies by 18.0% in the 1st quarter. Portolan Capital Management LLC now owns 1,605,599 shares of the biotechnology company’s stock valued at $1,718,000 after purchasing an additional 244,895 shares in the last quarter. Shay Capital LLC acquired a new position in shares of Applied Genetic Technologies in the 1st quarter valued at approximately $54,000. Finally, Empery Asset Management LP acquired a new position in shares of Applied Genetic Technologies in the 1st quarter valued at approximately $107,000. Hedge funds and other institutional investors own 38.03% of the company’s stock.
AGTC opened at $0.90 on Friday. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.73 and a quick ratio of 2.73. The stock has a market capitalization of $45.62 million, a price-to-earnings ratio of -0.62 and a beta of 1.65. The business has a 50-day moving average of $0.94 and a two-hundred day moving average of $1.61. Applied Genetic Technologies has a 12 month low of $0.58 and a 12 month high of $4.65.
About Applied Genetic Technologies (Get Rating)
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials.
Recommended Stories
Receive News & Ratings for Applied Genetic Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Applied Genetic Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.
Baidu, Inc. (NASDAQ:BIDU) Given Consensus Rating of “Buy” by Analysts